

# Contents

|                    |    |
|--------------------|----|
| Contributors ..... | xv |
|--------------------|----|

## **CHAPTER 1 Basics of epigenetics: It is more than simple changes in sequence that govern gene expression .....1**

Shilpy Sharma, Osama Aazmi

|                                                           |    |
|-----------------------------------------------------------|----|
| 1. Introduction.....                                      | 1  |
| 1.1 Genetics versus epigenetics .....                     | 1  |
| 2. Major epigenetic mechanisms .....                      | 3  |
| 2.1 DNA methylation.....                                  | 3  |
| 2.2 Histone modification.....                             | 5  |
| 2.3 Chromatin-modifying complexes .....                   | 6  |
| 2.4 Noncoding RNAs.....                                   | 7  |
| 3. Specific examples of epigenetic regulation .....       | 9  |
| 3.1 X chromosome inactivation .....                       | 9  |
| 3.2 Genomic imprinting.....                               | 9  |
| 3.3 Environmental effects .....                           | 9  |
| 3.4 Differential methylation and change in phenotype..... | 10 |
| 3.5 Epigenetic changes during development .....           | 10 |
| 4. Epigenetic dysregulation and human disease .....       | 11 |
| 5. Conclusions.....                                       | 11 |
| Acknowledgments .....                                     | 12 |
| References.....                                           | 12 |

## **CHAPTER 2 Epigenetic biomarkers for disease diagnosis .....21**

José Luis García-Giménez, Jesús Beltrán-García, Carlos Romá-Mateo,  
Marta Seco-Cervera, Gisselle Pérez-Machado, Salvador Mena-Mollá

|                                                                                      |    |
|--------------------------------------------------------------------------------------|----|
| 1. Introduction.....                                                                 | 21 |
| 2. Technologies for epigenetic biomarker analysis in clinical laboratories .....     | 22 |
| 2.1 DNA methylation assays.....                                                      | 23 |
| 2.2 miRNA analysis assays.....                                                       | 26 |
| 2.3 Analysis of histones and histone PTMs.....                                       | 29 |
| 3. Epigenetic biomarkers in the market .....                                         | 29 |
| 3.1 DNA methylation IVD tests.....                                                   | 29 |
| 3.2 miRNA IVD test .....                                                             | 33 |
| 4. Advantages and pitfalls for a clinical application of epigenetic biomarkers ..... | 35 |
| 5. Conclusions.....                                                                  | 36 |
| References.....                                                                      | 36 |

|                  |                                                                                                                                          |            |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------|
| <b>CHAPTER 3</b> | <b>Technological advances in studying epigenetics biomarkers of prognostic potential for clinical research</b>                           | <b>45</b>  |
|                  | Florence Mauger, Jean-François Deleuze                                                                                                   |            |
| 1.               | Introduction                                                                                                                             | 45         |
| 2.               | DNA methylation methods                                                                                                                  | 46         |
| 2.1              | Bisulfite methods                                                                                                                        | 46         |
| 2.2              | Affinity methods                                                                                                                         | 53         |
| 2.3              | Other technologies                                                                                                                       | 55         |
| 2.4              | Conclusion                                                                                                                               | 56         |
| 3.               | Histone modifications, nucleosome, and chromatin methods                                                                                 | 56         |
| 3.1              | Affinity antibody                                                                                                                        | 56         |
| 3.2              | Cleavage methods                                                                                                                         | 58         |
| 3.3              | Mass spectrometry                                                                                                                        | 58         |
| 3.4              | Chromatin accessibility                                                                                                                  | 58         |
| 3.5              | Chromatin conformation                                                                                                                   | 58         |
| 3.6              | DNA methylation-protein association                                                                                                      | 59         |
| 3.7              | Conclusion                                                                                                                               | 59         |
| 4.               | Noncoding RNA methods                                                                                                                    | 60         |
| 4.1              | miRNA methods                                                                                                                            | 60         |
| 4.2              | lncRNA methods                                                                                                                           | 63         |
| 5.               | Conclusion                                                                                                                               | 65         |
|                  | References                                                                                                                               | 66         |
| <b>CHAPTER 4</b> | <b>Use of circulating nucleic acids, metabolites, and proteins as clinical biomarkers for earlier prognosis and diagnosis of disease</b> | <b>85</b>  |
|                  | Ananthamohan Kalyani, Rakesh Mohan Jha, Shilpy Sharma                                                                                    |            |
| 1.               | Introduction                                                                                                                             | 85         |
| 2.               | Circulating biomarkers                                                                                                                   | 86         |
| 2.1              | Circulating extracellular vesicles/exosomes                                                                                              | 86         |
| 2.2              | Circulating tumor cells (CTCs)                                                                                                           | 90         |
| 2.3              | Circulating proteins                                                                                                                     | 90         |
| 2.4              | Circulating metabolites                                                                                                                  | 92         |
| 2.5              | Circulating nucleic acids (CNAs)                                                                                                         | 92         |
| 3.               | Conclusions                                                                                                                              | 100        |
|                  | Acknowledgments                                                                                                                          | 100        |
|                  | References                                                                                                                               | 101        |
| <b>CHAPTER 5</b> | <b>Deciphering ocular diseases on an epigenetic platform</b>                                                                             | <b>117</b> |
|                  | Arul J. Duraisamy, Manish Mishra, Sudarshan Bhattacharjee, Renu A. Kowluru                                                               |            |
| 1.               | Introduction                                                                                                                             | 117        |
| 2.               | Common ocular diseases                                                                                                                   | 118        |

|                  |                                                                    |            |
|------------------|--------------------------------------------------------------------|------------|
| 2.1              | Cataract.....                                                      | 118        |
| 2.2              | Age-related macular degeneration.....                              | 119        |
| 2.3              | Diabetic retinopathy.....                                          | 119        |
| 2.4              | Retinitis pigmentosa.....                                          | 119        |
| 2.5              | Retinoblastoma.....                                                | 119        |
| 2.6              | Glaucoma.....                                                      | 120        |
| 2.7              | Myopia.....                                                        | 120        |
| 3.               | Experimental models of eye diseases.....                           | 120        |
| 4.               | Epigenetics.....                                                   | 121        |
| 4.1              | DNA methylation.....                                               | 121        |
| 4.2              | Histone modifications.....                                         | 121        |
| 4.3              | Noncoding RNAs.....                                                | 122        |
| 5.               | Epigenetics and development of the eye.....                        | 122        |
| 6.               | Epigenetics and ocular diseases.....                               | 123        |
| 6.1              | Cataract.....                                                      | 124        |
| 6.2              | Age-related macular degeneration.....                              | 124        |
| 6.3              | Diabetic retinopathy.....                                          | 125        |
| 6.4              | Retinoblastoma.....                                                | 128        |
| 6.5              | Glaucoma.....                                                      | 129        |
| 6.6              | Myopia.....                                                        | 129        |
| 7.               | Epigenetic biomarkers in ocular diseases.....                      | 129        |
| 8.               | Epigenetic targets as therapeutics for ocular diseases.....        | 131        |
| 9.               | Conclusions.....                                                   | 131        |
|                  | References.....                                                    | 132        |
| <b>CHAPTER 6</b> | <b>Epigenetic biomarkers of asthma and allergic disorders.....</b> | <b>139</b> |
|                  | Maryam Akhtari, Mahdi Mahmoudi                                     |            |
| 1.               | Allergic diseases.....                                             | 139        |
| 2.               | Pathophysiology of allergic disorders.....                         | 139        |
| 3.               | Epigenetic modifications.....                                      | 140        |
| 3.1              | DNA methylation.....                                               | 142        |
| 3.2              | Noncoding RNAs.....                                                | 142        |
| 3.3              | Histone modifications.....                                         | 143        |
| 4.               | DNA methylation in allergic diseases.....                          | 143        |
| 4.1              | DNA methylation and asthma.....                                    | 144        |
| 4.2              | DNA methylation in allergic rhinitis and atopic dermatitis.....    | 148        |
| 5.               | miRNAs in allergic diseases.....                                   | 153        |
| 5.1              | miRNAs and asthma.....                                             | 153        |
| 5.2              | miRNA expression in allergic rhinitis and atopic dermatitis.....   | 155        |
| 6.               | Histone modification and allergic diseases.....                    | 156        |
| 7.               | Conclusions and future directions.....                             | 160        |
|                  | References.....                                                    | 160        |

|                                                                                                                     |                |
|---------------------------------------------------------------------------------------------------------------------|----------------|
| <b>CHAPTER 7 Epigenetics in infectious disease</b>                                                                  | <b>171</b>     |
| Abhishek Kanyal, Sunil Nahata, Krishanpal Karmodiya                                                                 |                |
| 1. Introduction                                                                                                     | 171            |
| 2. Epigenetic and transcriptional regulation induced by pathogens in host cells                                     | 172            |
| 3. Transcriptional regulation in infectious organisms                                                               | 175            |
| 3.1 DNA methylation                                                                                                 | 175            |
| 3.2 Posttranslational modifications of histones                                                                     | 178            |
| 3.3 Role of noncoding RNAs                                                                                          | 186            |
| 4. Epigenetic regulation, virulence, and pathogenicity in infectious diseases                                       | 189            |
| 4.1 In <i>P. falciparum</i>                                                                                         | 189            |
| 4.2 In <i>T. brucei</i>                                                                                             | 190            |
| 5. Epigenetic mechanisms as potent biomarkers and drug targets                                                      | 191            |
| 6. Conclusions                                                                                                      | 192            |
| Acknowledgments                                                                                                     | 192            |
| References                                                                                                          | 192            |
| <br><b>CHAPTER 8 Epigenetics of autoimmune diseases</b>                                                             | <br><b>203</b> |
| Elham Farhadi, Mahdi Mahmoudi                                                                                       |                |
| 1. Introduction                                                                                                     | 203            |
| 2. Epigenetic mechanisms                                                                                            | 204            |
| 2.1 DNA methylation                                                                                                 | 204            |
| 2.2 Histone modifications                                                                                           | 204            |
| 2.3 Noncoding RNA                                                                                                   | 205            |
| 3. The predominance of autoimmune diseases in females                                                               | 205            |
| 4. Environmental factors contribute to increased autoimmune disease susceptibility through epigenetic modifications | 205            |
| 4.1 Exposure to ultraviolet radiation                                                                               | 206            |
| 4.2 Diet                                                                                                            | 206            |
| 4.3 Drugs                                                                                                           | 207            |
| 4.4 Chemicals                                                                                                       | 207            |
| 4.5 Smoking                                                                                                         | 207            |
| 4.6 Infection                                                                                                       | 208            |
| 5. Internal factors                                                                                                 | 208            |
| 5.1 Oxidation                                                                                                       | 208            |
| 6. Systemic lupus erythematosus                                                                                     | 208            |
| 6.1 DNA methylation                                                                                                 | 208            |
| 6.2 Histone modifications                                                                                           | 210            |
| 6.3 miRNAs                                                                                                          | 213            |
| 7. Rheumatoid arthritis                                                                                             | 214            |
| 7.1 DNA methylation                                                                                                 | 214            |

|      |                                                    |     |
|------|----------------------------------------------------|-----|
| 7.2  | Histone modifications .....                        | 217 |
| 7.3  | miRNAs .....                                       | 218 |
| 8.   | Systemic sclerosis .....                           | 218 |
| 8.1  | DNA methylation .....                              | 218 |
| 8.2  | Histone modifications .....                        | 219 |
| 8.3  | miRNAs .....                                       | 220 |
| 9.   | Multiple sclerosis .....                           | 221 |
| 9.1  | DNA methylation .....                              | 221 |
| 9.2  | Histone modifications .....                        | 222 |
| 9.3  | miRNAs .....                                       | 222 |
| 10.  | Type 1 diabetes .....                              | 223 |
| 10.1 | DNA methylation .....                              | 223 |
| 10.2 | Histone modifications .....                        | 223 |
| 10.3 | miRNAs .....                                       | 224 |
| 11.  | Other autoimmune diseases .....                    | 225 |
| 11.1 | Ankylosing spondylitis .....                       | 225 |
| 11.2 | Inflammatory bowel disease .....                   | 225 |
| 11.3 | Sjögren's syndrome .....                           | 226 |
| 11.4 | Psoriasis .....                                    | 226 |
| 12.  | Epigenetic biomarkers in autoimmune diseases ..... | 227 |
| 13.  | Epigenetic therapy .....                           | 228 |
| 14.  | Conclusion .....                                   | 229 |
|      | References .....                                   | 230 |

## **CHAPTER 9 Epigenetic mechanisms underlying the pathogenesis of osteoarthritis and their clinical relevance .....**

Mingcai Zhang, Caleb Grote, Jinxi Wang

|     |                                                                                                      |     |
|-----|------------------------------------------------------------------------------------------------------|-----|
| 1.  | Introduction .....                                                                                   | 245 |
| 1.1 | Pathophysiology of primary OA .....                                                                  | 245 |
| 1.2 | OA study models .....                                                                                | 246 |
| 2.  | Current understanding of epigenetic mechanisms .....                                                 | 246 |
| 2.1 | DNA methylation .....                                                                                | 246 |
| 2.2 | Histone modifications .....                                                                          | 247 |
| 2.3 | Non-coding RNAs (ncRNAs) .....                                                                       | 248 |
| 2.4 | Crosstalk among the epigenetic mechanisms .....                                                      | 248 |
| 3.  | Epigenetic regulation of gene expression in development and maintenance of articular cartilage ..... | 250 |
| 3.1 | Sox9 .....                                                                                           | 251 |
| 3.2 | Nfat1 .....                                                                                          | 251 |
| 4.  | Epigenetic mechanisms underlying the aberrant metabolic activities of OA chondrocytes .....          | 253 |

|                                                                                                                                        |            |
|----------------------------------------------------------------------------------------------------------------------------------------|------------|
| 4.1 Epigenetic regulation of catabolic genes .....                                                                                     | 253        |
| 4.2 Epigenetic regulation of anabolic genes .....                                                                                      | 255        |
| 4.3 Dysregulation of gene expression in initiation and progression of OA .....                                                         | 257        |
| 5. Clinical relevance .....                                                                                                            | 258        |
| 6. Conclusion and future perspectives .....                                                                                            | 260        |
| 6.1 Conclusion .....                                                                                                                   | 260        |
| 6.2 Future perspectives .....                                                                                                          | 260        |
| Acknowledgments .....                                                                                                                  | 262        |
| Conflicts of interest .....                                                                                                            | 262        |
| References .....                                                                                                                       | 262        |
| <b>CHAPTER 10 Epigenetic biomarkers in metabolic syndrome and obesity .....</b>                                                        | <b>269</b> |
| Andrea G. Izquierdo, Ana B. Crujeiras                                                                                                  |            |
| 1. Introduction .....                                                                                                                  | 269        |
| 2. Epigenetic regulation: Overview .....                                                                                               | 271        |
| 3. Evidence of epigenetic modifications related to metabolic disorders .....                                                           | 272        |
| 3.1 DNA methylation pattern in obesity and metabolic syndrome .....                                                                    | 273        |
| 3.2 Other epigenetic marks in obesity and metabolic syndrome .....                                                                     | 275        |
| 3.3 Posttranslational histone modifications (PTMs) .....                                                                               | 276        |
| 4. Clinical applicability of epigenetic biomarkers for the obesity and metabolic syndrome management .....                             | 277        |
| 5. Conclusions .....                                                                                                                   | 279        |
| Acknowledgments .....                                                                                                                  | 281        |
| References .....                                                                                                                       | 281        |
| <b>CHAPTER 11 Chromatin landscape and epigenetic biomarkers for clinical diagnosis and prognosis of type 2 diabetes mellitus .....</b> | <b>289</b> |
| Eralda Asllanaj, Carolina Ochoa-Rosales, Marija Glisic, Jana Nano Taulant Muka, Oscar H. Franco                                        |            |
| 1. Introduction .....                                                                                                                  | 289        |
| 2. Epigenetic alterations involved in glucose homeostasis and insulin metabolism .....                                                 | 291        |
| 2.1 Glucose homeostasis .....                                                                                                          | 303        |
| 2.2 Insulin metabolism .....                                                                                                           | 304        |
| 3. Epigenetic alterations in diabetes .....                                                                                            | 306        |
| 3.1 DNA methylation .....                                                                                                              | 306        |
| 3.2 Histone modifications .....                                                                                                        | 307        |
| 4. Epigenetic mechanisms as biomarkers for risk prediction .....                                                                       | 308        |
| 4.1 DNA methylation .....                                                                                                              | 308        |
| 4.2 Histone modifications .....                                                                                                        | 309        |



|                   |                                                                                                                          |            |
|-------------------|--------------------------------------------------------------------------------------------------------------------------|------------|
| 5.                | Epigenetic changes associated with diabetic complications.....                                                           | 309        |
| 5.1               | Epigenetic modifications in cardiovascular disease .....                                                                 | 309        |
| 5.2               | Epigenetic modifications in diabetic nephropathy.....                                                                    | 311        |
| 5.3               | Epigenetic modifications in diabetic retinopathy .....                                                                   | 312        |
| 5.4               | Epigenetic modifications in diabetic neuropathy.....                                                                     | 313        |
| 6.                | Epigenetic-based biomarkers for diagnosis and prognosis of T2D .....                                                     | 314        |
| 6.1               | Epigenetic-based biomarkers for diagnosis of T2D .....                                                                   | 314        |
| 6.2               | Epigenetic-based biomarkers for prognosis of T2D.....                                                                    | 316        |
| 7.                | Conclusions and future research directions .....                                                                         | 317        |
|                   | Acknowledgment .....                                                                                                     | 318        |
|                   | References.....                                                                                                          | 318        |
| <b>CHAPTER 12</b> | <b>Epigenetic landscape of infertility .....</b>                                                                         | <b>325</b> |
|                   | Shilpa Bisht, Priyanka Chaurasia, Ansh Goswami, Saima Khan, Rima Dada                                                    |            |
| 1.                | Infertility: An overview.....                                                                                            | 325        |
| 2.                | Epigenetics: A step forward beyond the science of genetics .....                                                         | 326        |
| 3.                | Epigenetics and infertility: A road less traveled .....                                                                  | 328        |
| 4.                | Epigenetics of male infertility: Present knowledge and future prospects.....                                             | 329        |
| 4.1               | The genetic prospect of male infertility .....                                                                           | 329        |
| 4.2               | Epigenetics of male infertility: A new perspective .....                                                                 | 331        |
| 4.3               | Environment toxicants and sperm epigenome .....                                                                          | 333        |
| 5.                | Epigenetics of female infertility: What is known and what still needs to be explored .....                               | 334        |
| 5.1               | Environmental toxicants and female fertility.....                                                                        | 335        |
| 6.                | Genomic imprinting.....                                                                                                  | 336        |
| 7.                | Epigenetics of infertility and cancer .....                                                                              | 338        |
| 8.                | Conclusion .....                                                                                                         | 340        |
|                   | Glossary .....                                                                                                           | 342        |
|                   | References.....                                                                                                          | 343        |
| <b>CHAPTER 13</b> | <b>Histone posttranslational modifications: Potential role in diagnosis, prognosis, and therapeutics of cancer .....</b> | <b>351</b> |
|                   | Asmita Sharda, Ramchandra V. Amnekar, Abhiram Natu, Sukanya, Sanjay Gupta                                                |            |
| 1.                | Introduction.....                                                                                                        | 351        |
| 2.                | Histone posttranslational modification in cancer.....                                                                    | 352        |
| 2.1               | Histone acetylation .....                                                                                                | 352        |
| 2.2               | Histone methylation.....                                                                                                 | 354        |
| 2.3               | Histone phosphorylation.....                                                                                             | 357        |
| 2.4               | Histone ubiquitylation .....                                                                                             | 360        |

|                                                                                                                        |            |
|------------------------------------------------------------------------------------------------------------------------|------------|
| 2.5 Histone citrullination .....                                                                                       | 361        |
| 2.6 Histone ribosylation.....                                                                                          | 361        |
| 2.7 Histone sumoylation .....                                                                                          | 361        |
| 3. Future perspectives and limitations for clinical intervention.....                                                  | 362        |
| 4. Conclusion.....                                                                                                     | 365        |
| Acknowledgment .....                                                                                                   | 366        |
| Funding.....                                                                                                           | 366        |
| Author contributions .....                                                                                             | 366        |
| Competing interests .....                                                                                              | 366        |
| References.....                                                                                                        | 366        |
| <b>CHAPTER 14 Epigenetic biomarkers in personalized medicine .....</b>                                                 | <b>375</b> |
| Mohamad M. Kronfol, Joseph L. McClay                                                                                   |            |
| 1. Introduction.....                                                                                                   | 375        |
| 2. Cancer pharmacoeigenetics .....                                                                                     | 376        |
| 2.1 Alkylating compounds.....                                                                                          | 376        |
| 2.2 Anthracyclines .....                                                                                               | 378        |
| 2.3 Antimetabolites.....                                                                                               | 379        |
| 2.4 Hormonal therapy and antagonists .....                                                                             | 380        |
| 2.5 Microtubule inhibitors .....                                                                                       | 381        |
| 2.6 Platinum compounds .....                                                                                           | 381        |
| 2.7 Monoclonal antibodies.....                                                                                         | 382        |
| 2.8 Tyrosine kinase inhibitors.....                                                                                    | 383        |
| 3. Psychiatric disorder pharmacoeigenetics.....                                                                        | 383        |
| 3.1 Major depressive disorder (MDD).....                                                                               | 384        |
| 3.2 Schizophrenia .....                                                                                                | 384        |
| 4. Other pharmacoeigenetics examples .....                                                                             | 385        |
| 5. Summary.....                                                                                                        | 386        |
| References.....                                                                                                        | 389        |
| <b>CHAPTER 15 Conclusions and perspectives: Major challenges and future prospects for prognostic epigenetics .....</b> | <b>397</b> |
| Shilpy Sharma                                                                                                          |            |
| 1. Introduction.....                                                                                                   | 397        |
| 2. Epigenetic biomarkers .....                                                                                         | 397        |
| 2.1 Early diagnosis, classification, and prognosis .....                                                               | 398        |
| 2.2 Disease progression .....                                                                                          | 399        |
| 2.3 Therapeutic response assessment and personalized medicine.....                                                     | 399        |
| 3. Major challenges in epigenetic studies leading to epigenetics-based biomarker development .....                     | 399        |
| 3.1 Disease etiology.....                                                                                              | 400        |
| 3.2 Lack of suitable tissue sample and tissue heterogeneity .....                                                      | 400        |



## Contributors

|                                                                     |     |
|---------------------------------------------------------------------|-----|
| 3.3 Study population heterogeneity and environmental influence..... | 401 |
| 3.4 Gene and environmental interactions.....                        | 402 |
| 3.5 Establishment of the causal role of epigenetic changes.....     | 402 |
| 3.6 Technological challenges.....                                   | 403 |
| 4. Epigenetic therapy.....                                          | 403 |
| 5. Future perspectives and conclusions.....                         | 404 |
| Acknowledgments.....                                                | 404 |
| References.....                                                     | 405 |
| Index.....                                                          | 411 |